A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Gynecologic Oncology

Volumn 146, Issue 3, 2017, Pages 484-490

  Kristeleit, Rebecca ^a   Davidenko, Irina ^b   Shirinkin, Vadim ^c   El Khouly, Fatima ^a   Bondarenko, Igor ^d   Goodheart, Michael J ^e   Gorbunova, Vera ^f   Penning, Carol A ^g   Shi, Jack G ^g   Liu, Xiangdong ^g   Newton, Robert C ^g   Zhao, Yufan ^g   Maleski, Janet ^g   Leopold, Lance ^g   Schilder, Russell J ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Healthcare Department of Krasnodar Region   (Russian Federation)

^c Orenburg Regional Clinical Oncology Dispensary   (Russian Federation)

^d Dnipropetrovsk State Medical Academy   (Ukraine)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^g Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Ca 125; Epacadostat; IDO1 enzyme inhibitor; Ovarian cancer; Tamoxifen

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; BEVACIZUMAB; C REACTIVE PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPACADOSTAT; GEMCITABINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; OXIME; SULFONAMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; ASCITES; BIOCHEMICAL RECURRENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED PRACTICE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTHERMIA; INSOMNIA; MACULOPAPULAR RASH; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEROTONIN SYNDROME; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ERUPTIONS; EARLY TERMINATION OF CLINICAL TRIAL; FALLOPIAN TUBE NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECURRENT DISEASE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; EARLY TERMINATION OF CLINICAL TRIALS; EXANTHEMA; FALLOPIAN TUBE NEOPLASMS; FATIGUE; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIMES; PERITONEAL NEOPLASMS; PRURITUS; RECURRENCE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SULFONAMIDES; SURVIVAL RATE; TAMOXIFEN;

EID: 85021862031     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.07.005     Document Type: Article

References (35)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology. Ovarian Cancer. Version 1.2016. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
3. Doufekas, K., Olaitan, A., Clinical epidemiology of epithelial ovarian cancer in the UK. Int. J. Womens Health 6 (2014), 537–545.
4. Jelovac, D., Armstrong, D.K., Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61 (2011), 183–203.
5. Luvero, D., Milani, A., Ledermann, J.A., Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 6 (2014), 229–239.
6. Ledermann, J.A., Kristeleit, R.S., Optimal treatment for relapsing ovarian cancer. Ann. Oncol. 21 (2010), vii218–vii222.
7. Menon, U., Skates, S.J., Lewis, S., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23 (2005), 7919–7926.
8. Yigit, R., Massuger, L.F.A.G., Figdor, C.G., Torensma, R., Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol. Oncol. 117 (2010), 366–372.
9. Cannon, M.J., O'Brien, T.J., Cellular immunotherapy for ovarian cancer. Expert. Opin. Biol. Ther. 9 (2009), 677–688.
10. Curiel, T.J., Coukos, G., Zou, L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
11. Clarke, B., Tinker, A.V., Lee, C.H., et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22 (2009), 393–402.
12. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003), 203–213.
13. Uyttenhove, C., Pilotte, L., Théate, I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003), 1269–1274.
14. Munn, D.H., Sharma, M.D., Hou, D., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004), 280–290.
15. Inaba, T., Ino, K., Kajiyama, H., et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 115 (2009), 185–192.
16. Okamoto, A., Nikaido, T., Ochiai, K., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11 (2005), 6030–6039.
17. Takao, M., Okamoto, A., Nikaido, T., et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol. Rep. 17 (2007), 1333–1339.
18. Mellor, A.L., Munn, D.H., Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. 170 (2003), 5809–5813.
19. Ino, K., Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr. Opin. Obstet. Gynecol. 23 (2011), 13–18.
20. Liu, X., Shin, N., Koblish, H.K., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115 (2010), 3520–3530.
21. Jochems, C., Kwilas, A., Kim, Y.-S., et al. The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro. J. Clin. Oncol., 33, 2015, e14012.
22. Newton, R.C., Scherle, P.A., Bowman, K., et al. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. J. Clin. Oncol., 30, 2012, 2500.
23. Beatty, G.L., O'Dwyer, P.J., Clark, J., et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J. Clin. Oncol., 31, 2013, 3025.
24. Edge, S., Ovary and primary peritoneal carcinoma. Edge, S., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A., (eds.) AJCC Cancer Staging Manual, 7th ed, 2010, Springer-Verlag, New York, NY, 419–428.
25. Beatty, G.L., O'Dwyer, P.J., Clark, J., et al. First-in-human phase 1 study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin. Cancer Res., 2017.
26. Allin, K.H., Nordestgaard, B.G., Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit. Rev. Clin. Lab. Sci. 48 (2011), 155–170.
27. Shrotriya, S., Walsh, D., Bennani-Baiti, N., Thomas, S., Lorton, C., C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One, 10, 2015, e0143080.
28. Hurteau, J.A., Brady, M.F., Darcy, K.M., et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a gynecologic oncology group study. Gynecol. Oncol. 119 (2010), 444–450.
29. Morrissey, K.M., Yuraszeck, T.M., Li, C.C., Zhang, Y., Kasichayanula, S., Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Trans. Sci. 9 (2016), 89–104.
30. Munn, D.H., Mellor, A.L., Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34 (2013), 137–143.
31. Prendergast, G.C., Chang, M.Y., Mandik-Nayak, L., Metz, R., Muller, A.J., Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18 (2011), 2257–2262.
32. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005), 312–319.
33. Grabosch, S., Zeng, F., Zhang, L., et al. PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer. J. Immunother. Cancer, 3, 2015, P302.
34. Mittica, G., Genta, S., Aglietta, M., Valabrega, G., Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?. Int. J. Mol. Sci., 17, 2016, 1169.
35. Gibney, G.T., Hamid, O., Gangadhar, T.C., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J. Clin. Oncol., 32, 2014, 3010.